What will shape the Pharma landscape in Q3 2025?
Upcoming drug approvals and clinical progress will be pivotal during the third quarter of the year, says GlobalData.
List view / Grid view
Upcoming drug approvals and clinical progress will be pivotal during the third quarter of the year, says GlobalData.
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of a variety of new medicines, including several treatments for hereditary and rare conditions.
The global market for growth hormone deficiency (GHD) treatment will rise in value from $1.26 billion in 2014 to reach approximately $1.88 billion by 2024, representing a moderate Compound Annual Growth Rate (CAGR) of 4.08%, according to research and consulting firm GlobalData.